LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

Presbyopia is the inevitable loss of near vision that impacts an estimated 1.8B people globally and 128 million people in the United States.

VIZZ provides an ideal pharmaceutical presbyopia solution to restore near vision, with the potential for broadest target patient population.

Our team is filled with ambitious individuals from across the pharmaceutical and eye care industry who are motivated to improve vision.

Stay up to date with recent news from LENZ Therapeutics and see latest presentations. Click link below to download the Corporate Presentation.